NextGen Healthcare, Inc. (NASDAQ:NXGN) shares rose more than 4% on Tuesday following the company’s pre-announced Q4 results (the official earnings date is May 17).

The preliminary unaudited Q4 revenue of $150-152 million came in above the consensus estimate of $148 million, while EPS of $0.18-0.20 was slightly below the consensus estimate of $0.20 at the midpoint.

The company provided its full 2023-year outlook, with revenue and EPS guidance of $628-640 million and $0.95-1.01, compared to the consensus estimates of $624 million and $1.00, respectively. This reflects 5.4-7.4% year-over-year revenue growth from the midpoint of the pre-announced range for 2022 and is largely consistent with the 6-8% target management discussed in January.